{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:30:56Z","timestamp":1792812656570,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["NU52PS910232"],"award-info":[{"award-number":["NU52PS910232"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.josat.2025.209670","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:35:52Z","timestamp":1741221352000},"page":"209670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Barriers and facilitators to buprenorphine delivery: Results from a qualitative study of syringe services provider experiences"],"prefix":"10.1016","volume":"172","author":[{"given":"Sarah M.","family":"Philbrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn D.","family":"Wenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher F.","family":"Akiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hairgrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansel","family":"Tookes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex H.","family":"Kral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barrot H.","family":"Lambdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila V.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2025.209670_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ssmqr.2024.100421","article-title":"Financial barriers, facilitators, and strategies among syringe services programs in the U.S., and their impact on implementation and health outcomes","volume":"5","author":"Akiba","year":"2024","journal-title":"SSM - Qualitative Research in Health"},{"key":"10.1016\/j.josat.2025.209670_bb0010","series-title":"The ASAM National Practice Guideline for the treatment of opioid use disorder: 2020 focused update","author":"American Society of Addiction Medicine (ASAM)","year":"2020"},{"issue":"2","key":"10.1016\/j.josat.2025.209670_bb0015","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/08897077.2018.1443541","article-title":"Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program","volume":"39","author":"Bachhuber","year":"2018","journal-title":"Substance Abuse"},{"issue":"1","key":"10.1016\/j.josat.2025.209670_bb0020","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12954-023-00861-3","article-title":"Availability of telehealth-based services at syringe services programs under the COVID-19 Public Health Emergency","volume":"20","author":"Bartholomew","year":"2023","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.josat.2025.209670_bb0025","unstructured":"Chung, E. (Under Review). Safer smoking pipe distribution and scale of harm reduction services: findings from the National Survey of Syringe Services Programs in the United States."},{"key":"10.1016\/j.josat.2025.209670_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.dadr.2024.100317","article-title":"Association of safer smoking supply distribution with participant encounters and naloxone distribution from syringe services programs: Findings from the National Survey of Syringe Services Programs in the United States","volume":"14","author":"Chung","year":"2025","journal-title":"Drug and Alcohol Dependence Reports"},{"issue":"4","key":"10.1016\/j.josat.2025.209670_bb0035","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1176\/appi.ps.54.4.501","article-title":"Factors that explain how policy makers distribute resources to mental health services","volume":"54","author":"Corrigan","year":"2003","journal-title":"Psychiatric Services"},{"issue":"5","key":"10.1016\/j.josat.2025.209670_bb0040","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1097\/ADM.0000000000000618","article-title":"Rapid transition from methadone to buprenorphine utilizing a micro-dosing protocol in the outpatient veteran affairs setting","volume":"14","author":"De Aquino","year":"2020","journal-title":"Journal of Addiction Medicine"},{"issue":"1","key":"10.1016\/j.josat.2025.209670_bb0045","first-page":"6","article-title":"Does individual stigma predict mental health funding attitudes? Toward an understanding of resource allocation and social climate","volume":"54","author":"DeLuca","year":"2017","journal-title":"The Israel Journal of Psychiatry and Related Sciences"},{"issue":"4","key":"10.1016\/j.josat.2025.209670_bb0050","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1080\/08897077.2021.1915914","article-title":"Rapid buprenorphine microdosing for opioid use disorder in a hospitalized patient receiving very high doses of full agonist opioids for acute pain management: Titration, implementation barriers, and strategies to overcomes","volume":"42","author":"DeWeese","year":"2021","journal-title":"Substance Abuse"},{"issue":"1","key":"10.1016\/j.josat.2025.209670_bb0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42685","article-title":"Overdose and homelessness-why we need to talk about housing","volume":"5","author":"Doran","year":"2022","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2025.209670_bb0060","first-page":"2850","article-title":"Thinking about the coding process in qualitative data analysis","volume":"23","author":"Elliott","year":"2018","journal-title":"Qualitative Report"},{"issue":"4","key":"10.1016\/j.josat.2025.209670_bb0065","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2105\/AJPH.2024.307583","article-title":"Funding and delivery of syringe services programs in the United States, 2022","volume":"114","author":"Facente","year":"2024","journal-title":"American Journal of Public Health"},{"issue":"S1","key":"10.1016\/j.josat.2025.209670_bb0070","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1097\/QAI.0000000000002981","article-title":"The setting-intervention fit of nine evidence-based interventions for substance use disorders within HIV service organizations across the United States: Results of a National Stakeholder-Engaged Real-Time Delphi Study","volume":"90","author":"Garner","year":"2022","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"4","key":"10.1016\/j.josat.2025.209670_bb0075","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s10900-023-01278-6","article-title":"Community support for harm reduction and treatment of opioid use disorder","volume":"49","author":"Hanson","year":"2024","journal-title":"Journal of Community Health"},{"key":"10.1016\/j.josat.2025.209670_bb0080","author":"Harvard Health Blog"},{"issue":"5","key":"10.1016\/j.josat.2025.209670_bb0085","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1001\/archpsyc.58.5.503","article-title":"A 33-year follow-up of narcotics addicts","volume":"58","author":"Hser","year":"2001","journal-title":"Archives of General Psychiatry"},{"issue":"9","key":"10.1016\/j.josat.2025.209670_bb0090","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/1049732305276687","article-title":"Three approaches to qualitative content analysis","volume":"15","author":"Hsieh","year":"2005","journal-title":"Qualitative Health Research"},{"issue":"8","key":"10.1016\/j.josat.2025.209670_bb0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.27488","article-title":"Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021","volume":"6","author":"Jones","year":"2023","journal-title":"JAMA Network Open"},{"issue":"4","key":"10.1016\/j.josat.2025.209670_bb0100","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5811\/westjem.2022.2.52978","article-title":"Improving uptake of emergency department-initiated buprenorphine: Barriers and solutions","volume":"23","author":"Kelly","year":"2022","journal-title":"The Western Journal of Emergency Medicine"},{"key":"10.1016\/j.josat.2025.209670_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108256","article-title":"Supportive alternate site provision of buprenorphine: Overcoming barriers and improving patient outcomes","volume":"123","author":"Khan","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"9","key":"10.1016\/j.josat.2025.209670_bb0110","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine treatment divide by race\/ethnicity and payment","volume":"76","author":"Lagisetty","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.josat.2025.209670_bb0115","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13011-022-00483-1","article-title":"Improving equity and access to buprenorphine treatment through telemedicine at syringe services programs","volume":"17","author":"Lambdin","year":"2022","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"key":"10.1016\/j.josat.2025.209670_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109504","article-title":"Buprenorphine implementation at syringe service programs following waiver of the Ryan Haight Act in the United States","volume":"237","author":"Lambdin","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.josat.2025.209670_bb0125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12954-023-00755-4","article-title":"How do contextual factors influence naloxone distribution from syringe service programs in the USA: A cross-sectional study","volume":"20","author":"Lambdin","year":"2023","journal-title":"Harm Reduction Journal"},{"issue":"5","key":"10.1016\/j.josat.2025.209670_bb0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.12419","article-title":"Survey of barriers and facilitators to prescribing buprenorphine and clinician perceptions on the drug addiction treatment act of 2000 waiver","volume":"5","author":"Lanham","year":"2022","journal-title":"JAMA Network Open"},{"issue":"10118","key":"10.1016\/j.josat.2025.209670_bb0135","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.josat.2025.209670_bb0140","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1001\/jama.2023.5038","article-title":"Changes in waivered clinicians prescribing buprenorphine and prescription volume by patient limit","volume":"329","author":"Luo","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.josat.2025.209670_bb0145","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1465-3362.2010.00188.x","article-title":"Needle exchange as a safe haven in an unsafe world","volume":"30","author":"MacNeil","year":"2011","journal-title":"Drug and Alcohol Review"},{"key":"10.1016\/j.josat.2025.209670_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2024.111130","article-title":"\u201cI want to stay here\u201d: Patient and staff perspectives on transitioning from a low-threshold buprenorphine program to clinic-based care","volume":"257","author":"Martinez","year":"2024","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2025.209670_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.dadr.2023.100155","article-title":"Changes in buprenorphine visits in frontier and remote locations: Effects of the SARS-CoV-2 pandemic","volume":"7","author":"McFadden","year":"2023","journal-title":"Drug and Alcohol Dependence Reports"},{"issue":"8","key":"10.1016\/j.josat.2025.209670_bb0160","doi-asserted-by":"crossref","first-page":"ofab289","DOI":"10.1093\/ofid\/ofab289","article-title":"A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes","volume":"8","author":"McNamara","year":"2021","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1016\/j.josat.2025.209670_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2020.106551","article-title":"Effectiveness of micro-induction approaches to buprenorphine initiation: A systematic review protocol","volume":"111","author":"Moe","year":"2020","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.josat.2025.209670_bb0170","doi-asserted-by":"crossref","first-page":"1334850","DOI":"10.3389\/fpubh.2024.1334850","article-title":"The development of a recovery coaching training curriculum to facilitate linkage to and increase retention on medications for opioid use disorder","volume":"12","author":"Moffitt","year":"2024","journal-title":"Frontiers in Public Health"},{"issue":"1","key":"10.1016\/j.josat.2025.209670_bb0175","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12954-020-00399-8","article-title":"\u201cThey look at us like junkies\u201d: Influences of drug use stigma on the healthcare engagement of people who inject drugs in new York City","volume":"17","author":"Muncan","year":"2020","journal-title":"Harm Reduction Journal"},{"issue":"1","key":"10.1016\/j.josat.2025.209670_bb0180","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12954-024-00971-6","article-title":"Structural stigma within inpatient care for people who inject drugs: Implications for harm reduction","volume":"21","author":"Rehman","year":"2024","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.josat.2025.209670_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2024.104381","article-title":"Buprenorphine dispensing before and after the April 2021 X-Waiver exemptions: An interrupted time series analysis","volume":"126","author":"Roy","year":"2024","journal-title":"The International Journal on Drug Policy"},{"key":"10.1016\/j.josat.2025.209670_bb0190","unstructured":"SAMHSA. (n.d.). Harm reduction framework. Retrieved from https:\/\/www.samhsa.gov\/sites\/default\/files\/harm-reduction-framework.pdf."},{"issue":"6","key":"10.1016\/j.josat.2025.209670_bb0195","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40263-019-00637-z","article-title":"Buprenorphine treatment for opioid use disorder: An overview","volume":"33","author":"Shulman","year":"2019","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.josat.2025.209670_bb0200","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.5996","article-title":"Changes in US clinician waivers to prescribe buprenorphine management for opioid use disorder during the COVID-19 pandemic and after relaxation of training requirements","volume":"5","author":"Spetz","year":"2022","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2025.209670_bb0205","series-title":"Early intervention, treatment, and management of substance use disorders. In Facing Addiction in America: The Surgeon General\u2019s Report on Alcohol, Drugs, and Health","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)","year":"2016"},{"key":"10.1016\/j.josat.2025.209670_bb0210","series-title":"Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on Drug Use and Health (HHS Publication No. SMA 17-5044, NSDUH Series H-52)","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)","year":"2017"},{"key":"10.1016\/j.josat.2025.209670_bb0215","series-title":"Key substance use and mental health indicators in the United States: Results from the 2022 National Survey on Drug Use and Health (HHS Publication No. PEP23-07-01-006, NSDUH Series H-58)","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)","year":"2023"},{"key":"10.1016\/j.josat.2025.209670_bb0220","series-title":"Third temporary extension of COVID-19 telemedicine flexibilities for prescription of controlled medications 89 FR 91253","first-page":"91253","year":"2024"},{"issue":"2","key":"10.1016\/j.josat.2025.209670_bb0225","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1098214005283748","article-title":"A general inductive approach for analyzing qualitative evaluation data","volume":"27","author":"Thomas","year":"2006","journal-title":"American Journal of Evaluation"},{"key":"10.1016\/j.josat.2025.209670_bb0230","author":"U.S. Department of Health and Human Services"},{"key":"10.1016\/j.josat.2025.209670_bb0235","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.trsl.2021.03.011","article-title":"Ingenuity and resiliency of syringe service programs on the front lines of the opioid overdose and COVID-19 crises","volume":"234","author":"Wenger","year":"2021","journal-title":"Translational Research"},{"key":"10.1016\/j.josat.2025.209670_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.109782","article-title":"Community-, network-, and individual-level predictors of uptake of medication for opioid use disorder among young people who inject drugs and their networks: A multilevel analysis","volume":"244","author":"Williams","year":"2023","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.josat.2025.209670_bb0245","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s43058-021-00146-5","article-title":"A more practical guide to incorporating health equity domains in implementation determinant frameworks","volume":"2","author":"Woodward","year":"2021","journal-title":"Implementation Science Communications"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925000499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925000499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T02:48:31Z","timestamp":1745030911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875925000499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":49,"alternative-id":["S2949875925000499"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2025.209670","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Barriers and facilitators to buprenorphine delivery: Results from a qualitative study of syringe services provider experiences","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2025.209670","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"209670"}}